Abstract |
In a randomized, double-blind, large, simple trial, the safety and efficacy of two weight-adjusted dose levels of stavudine were evaluated in patients with advanced human immunodeficiency virus ( HIV) infection. All patients were refractory to or intolerant of both zidovudine and didanosine. Patients weighing > or = 60 kg received 20 or 40 mg of stavudine twice daily. The dose was reduced to 15 or 30 mg for patients weighing 40-59 kg and to 10 or 20 mg for those weighing < 40 kg. The primary efficacy end points were survival and time to clinical progression of HIV disease. The primary safety end point was time to dose-limiting neuropathy. A total of 8127 patients were enrolled as of 31 July 1993. Although many patients who might have benefitted from stavudine were reached by the parallel-track program, a review of demographic data revealed disproportionate representation by white men from large metropolitan areas on both coasts.
|
Authors | R E Anderson, L M Dunkle, L Smaldone, M Adler, C Wirtz, D Kriesel, A Cross, R R Martin |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 171 Suppl 2
Pg. S118-22
(Mar 1995)
ISSN: 0022-1899 [Print] United States |
PMID | 7861016
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Body Weight
- Double-Blind Method
- Female
- HIV Infections
(drug therapy)
- Humans
- Male
- Peripheral Nervous System Diseases
(chemically induced)
- Regression Analysis
- Stavudine
(administration & dosage, adverse effects, therapeutic use)
- Survival Rate
|